1
|
Abe M, Coleman JS, Presley CC, Schley ND, Lindsley CW. Rapid sp 3-Enriched Scaffold Generation via a Selective Aziridine Amide Ring-Opening Reaction. J Org Chem 2024; 89:3500-3508. [PMID: 38340064 PMCID: PMC10913065 DOI: 10.1021/acs.joc.3c02952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Revised: 01/22/2024] [Accepted: 01/25/2024] [Indexed: 02/12/2024]
Abstract
Sp3-enriched small molecules play a critical role in developing drug candidates. While designing analogues with greater sp3 character, a methodology utilizing a less explored cyclic-aziridine amide ring-opening reaction to generate sp3-enriched scaffolds has been developed and reported. This methodology enables rapid access to substructures with higher fsp3 values, attracting greater attention within the past few decades. The reaction exhibits a wide reaction scope, featuring a highly sterically hindered phenolic ether, thiophenolic ethers, protected aniline formations, and aliphatic/heteroaromatic ring-containing aziridine amides as substrates. Additionally, this reaction provides access to congested tertiary ether formations through regioselective transformation, applicable to an extensive range of drug discovery targets, construction of complex small molecules, and natural product syntheses. The scaffolds developed show improved physicochemical properties.
Collapse
Affiliation(s)
- Masahito Abe
- Warren
Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Franklin, Tennessee 37067, United States
| | - Jeremy S. Coleman
- Warren
Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Franklin, Tennessee 37067, United States
| | - Christopher C. Presley
- Warren
Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Franklin, Tennessee 37067, United States
| | - Nathan D. Schley
- Department
of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States
| | - Craig W. Lindsley
- Warren
Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Franklin, Tennessee 37067, United States
- Department
of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States
- Department
of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
| |
Collapse
|
2
|
Li Q, Deng X, Xu YJ, Dong L. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. J Med Chem 2023; 66:11593-11631. [PMID: 37647598 DOI: 10.1021/acs.jmedchem.3c00412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Considerable effort has been made to achieve less frequent dosing in the development of DPP-4 inhibitors. Enthusiasm for long-acting DPP-4 inhibitors is based on the promise that such agents with less frequent dosing regimens are associated with improved patient adherence, but the rational design of long-acting DPP-4 inhibitors remains a major challenge. In this Perspective, the development of long-acting DPP-4 inhibitors is comprehensively summarized to highlight the evolution of initial lead compounds on the path toward developing long-acting DPP-4 inhibitors over nearly three decades. The determinants for long duration of action are then examined, including the nature of the target, potency, binding kinetics, crystal structures, selectivity, and preclinical and clinical pharmacokinetic and pharmacodynamic profiles. More importantly, several possible approaches for the rational design of long-acting drugs are discussed. We hope that this information will facilitate the design and development of safer and more effective long-acting DPP-4 inhibitors and other oral drugs.
Collapse
Affiliation(s)
- Qing Li
- College of Chemistry and Materials Science, Sichuan Normal University, Chengdu 610068, China
| | - Xiaoyan Deng
- College of Chemistry and Materials Science, Sichuan Normal University, Chengdu 610068, China
| | - Yan-Jun Xu
- College of Chemistry and Materials Science, Sichuan Normal University, Chengdu 610068, China
| | - Lin Dong
- West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| |
Collapse
|
3
|
Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay. Molecules 2023; 28:molecules28031004. [PMID: 36770672 PMCID: PMC9921777 DOI: 10.3390/molecules28031004] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 12/31/2022] [Accepted: 01/04/2023] [Indexed: 01/20/2023] Open
Abstract
Recent research on dipeptidyl peptidase-IV (DPP-IV) inhibitors has made it feasible to treat type 2 diabetes mellitus (T2DM) with minimal side effects. Therefore, in the present investigation, we aimed to discover and develop some coumarin-based sulphonamides as potential DPP-IV inhibitors in light of the fact that molecular hybridization of many bioactive pharmacophores frequently results in synergistic activity. Each of the proposed derivatives was subjected to an in silico virtual screening, and those that met all of the criteria and had a higher binding affinity with the DPP-IV enzyme were then subjected to wet lab synthesis, followed by an in vitro biological evaluation. The results of the pre-ADME and pre-tox predictions indicated that compounds 6e, 6f, 6h, and 6m to 6q were inferior and violated the most drug-like criteria. It was observed that 6a, 6b, 6c, 6d, 6i, 6j, 6r, 6s, and 6t displayed less binding free energy (PDB ID: 5Y7H) than the reference inhibitor and demonstrated drug-likeness properties, hence being selected for wet lab synthesis and the structures being confirmed by spectral analysis. In the in vitro enzyme assay, the standard drug Sitagliptin had an IC50 of 0.018 µM in the experiment which is the most potent. All the tested compounds also displayed significant inhibition of the DPP-IV enzyme, but 6i and 6j demonstrated 10.98 and 10.14 µM IC50 values, respectively, i.e., the most potent among the synthesized compounds. Based on our findings, we concluded that coumarin-based sulphonamide derivatives have significant DPP-IV binding ability and exhibit optimal enzyme inhibition in an in vitro enzyme assay.
Collapse
|
4
|
Kumar Singh S, Suresh M, Bahadur Singh R, Bandichhor R, Ghosh P. A solvent free tandem lactamization-decarboxylation route to (S)-Pregabalin lactam. Tetrahedron Lett 2022. [DOI: 10.1016/j.tetlet.2022.153903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Chavan PA, Jadhav SB. Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'-
[(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy
drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes
Mellitus. LETT DRUG DES DISCOV 2022. [DOI: 10.2174/1570180818666210901125958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
One of the leading global metabolic diseases marked by insulin resistance and
chronic hyperglycemia is type 2 diabetes mellitus (T2DM). Since the last decade, DPP-4 enzyme inhibition
has proven to be a successful, safe, and well-established therapy for the treatment of T2DM.
Objective:
The present work reports the synthesis, characterization, and screening of some novel 2-
methyl-N'-[(Z)-substituted-phenyl ethylidene] imidazo [1, 2-a] pyridine-3-carbohydrazide derivatives as
DPP-IV inhibitors for the treatment of T2DM.
Methods:
The molecular docking was performed to study these derivatives' binding mode in the enzyme's
allosteric site. All the synthesized compounds were subjected for DPP-IV enzyme assay and in vivo antihyperglycemic
activity in STZ-induced diabetic rats.
Results:
The synthesized derivatives exhibited potent antidiabetic activity as compared to the standard
drug Sitagliptin. Out of sixteen compounds, A1, A4, B4, C2, C3, and D4 have shown promising antidiabetic
activity against the DPP-IV enzyme. The most promising compound, C2, showed a percentage inhibition
of 72.02±0.27 at 50 μM concentration. On the 21st-day, compound C2 showed a significant reduction
in serum blood glucose level, i.e., 156.16±4.87 mg/dL, then diabetic control, which was
280.00±13.29 mg/dL whereas, standard Sitagliptin showed 133.50±11.80 mg/dL. In the in vivo antihyperglycemic
activity, the compounds have exhibited good hypoglycemic potential in fasting blood glucose
in the T2DM animal model. All the docked molecules have exhibited perfect binding affinity towards
the active pocket of the enzyme. The synthesized derivatives were screened through Lipinski's rule
of five for better optimization, and fortunately, none of them violated the rule.
Conclusion:
The above results indicate that compound C2 is a relatively active and selective hit molecule
that can be structurally modified to enhance the DPP-IV inhibitor's potency and overall pharmacological
profile. From the present work, it has been concluded that substituted pyridine-3-carbohydrazide derivatives
possess excellent DPP-IV inhibitory potential and can be better optimized further by generating
more in vivo, in vitro models.
Collapse
Affiliation(s)
- Prerana A. Chavan
- Department of Pharmaceutical Chemistry, PES\'s Modern College of Pharmacy, Nigdi, Pune, Maharashtra 411044,
India
| | - Shailaja B. Jadhav
- Department of Pharmaceutical Chemistry, PES\'s Modern College of Pharmacy, Nigdi, Pune, Maharashtra 411044,
India
| |
Collapse
|
6
|
Hermansyah O, Bustamam A, Yanuar A. Virtual screening of dipeptidyl peptidase-4 inhibitors using quantitative structure-activity relationship-based artificial intelligence and molecular docking of hit compounds. Comput Biol Chem 2021; 95:107597. [PMID: 34800858 DOI: 10.1016/j.compbiolchem.2021.107597] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Revised: 10/25/2021] [Accepted: 10/26/2021] [Indexed: 12/31/2022]
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors are becoming an essential drug in the treatment of type 2 diabetes mellitus; however, some classes of these drugs exert side effects, including joint pain and pancreatitis. Studies suggest that these side effects might be related to secondary inhibition of DPP-8 and DPP-9. In this study, we identified DPP-4-inhibitor hit compounds selective against DPP-8 and DPP-9. We built a virtual screening workflow using a quantitative structure-activity relationship (QSAR) strategy based on artificial intelligence to allow faster screening of millions of molecules for the DPP-4 target relative to other screening methods. Five regression machine learning algorithms and four classification machine learning algorithms were applied to build virtual screening workflows, with the QSAR model applied using support vector regression (R2pred 0.78) and the classification QSAR model using the random forest algorithm with 92.2% accuracy. Virtual screening results of > 10 million molecules obtained 2 716 hits compounds with a pIC50 value of > 7.5. Additionally, molecular docking results of several potential hit compounds for DPP-4, DPP-8, and DPP-9 identified CH0002 as showing high inhibitory potential against DPP-4 and low inhibitory potential for DPP-8 and DPP-9 enzymes. These results demonstrated the effectiveness of this technique for identifying DPP-4-inhibitor hit compounds selective for DPP-4 and against DPP-8 and DPP-9 and suggest its potential efficacy for applications to discover hit compounds of other targets.
Collapse
Affiliation(s)
- Oky Hermansyah
- Laboratory of Biomedical Computation and Drug Design, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia
| | - Alhadi Bustamam
- Department of Mathematics, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok 16424, Indonesia
| | - Arry Yanuar
- Laboratory of Biomedical Computation and Drug Design, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
| |
Collapse
|
7
|
Subbaiah MAM, Meanwell NA. Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design. J Med Chem 2021; 64:14046-14128. [PMID: 34591488 DOI: 10.1021/acs.jmedchem.1c01215] [Citation(s) in RCA: 168] [Impact Index Per Article: 56.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The benzene moiety is the most prevalent ring system in marketed drugs, underscoring its historic popularity in drug design either as a pharmacophore or as a scaffold that projects pharmacophoric elements. However, introspective analyses of medicinal chemistry practices at the beginning of the 21st century highlighted the indiscriminate deployment of phenyl rings as an important contributor to the poor physicochemical properties of advanced molecules, which limited their prospects of being developed into effective drugs. This Perspective deliberates on the design and applications of bioisosteric replacements for a phenyl ring that have provided practical solutions to a range of developability problems frequently encountered in lead optimization campaigns. While the effect of phenyl ring replacements on compound properties is contextual in nature, bioisosteric substitution can lead to enhanced potency, solubility, and metabolic stability while reducing lipophilicity, plasma protein binding, phospholipidosis potential, and inhibition of cytochrome P450 enzymes and the hERG channel.
Collapse
Affiliation(s)
- Murugaiah A M Subbaiah
- Department of Medicinal Chemistry, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, Karnataka 560099, India
| | - Nicholas A Meanwell
- Department of Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
8
|
Qian XK, Zhang J, Li XD, Song PF, Zou LW. Research Progress on Dipeptidyl Peptidase Family: Structure, Function and Xenobiotic Metabolism. Curr Med Chem 2021; 29:2167-2188. [PMID: 34525910 DOI: 10.2174/0929867328666210915103431] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 07/23/2021] [Accepted: 07/25/2021] [Indexed: 11/22/2022]
Abstract
Prolyl-specific peptidases or proteases, including Dipeptidyl Peptidase 2, 4, 6, 8, 9, 10, Fibroblast Activation Protein, prolyl endopeptidase and prolyl carboxypeptidase, belong to the dipeptidyl peptidase family. In human physiology and anatomy, they have homology amino acid sequences, similarities in structure, but play distinct functions and roles. Some of them also play important roles in the metabolism of drugs containing endogenous peptides, xenobiotics containing peptides, and exogenous peptides. The major functions of these peptidases in both the metabolism of human health and bioactive peptides are of significant importance in the development of effective inhibitors to control the metabolism of endogenous bioactive peptides. The structural characteristics, distribution of tissue, endogenous substrates, and biological functions were summarized in this review. Furthermore, the xenobiotics metabolism of the dipeptidyl peptidase family is illustrated. All the evidence and information summarized in this review would be very useful for researchers to extend the understanding of the proteins of these families and offer advice and assistance in physiology and pathology studies.
Collapse
Affiliation(s)
- Xing-Kai Qian
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai. China
| | - Jing Zhang
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai. China
| | - Xiao-Dong Li
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai. China
| | - Pei-Fang Song
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai. China
| | - Li-Wei Zou
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai. China
| |
Collapse
|
9
|
Nicholls RA, Joosten RP, Long F, Wojdyr M, Lebedev A, Krissinel E, Catapano L, Fischer M, Emsley P, Murshudov GN. Modelling covalent linkages in CCP4. Acta Crystallogr D Struct Biol 2021; 77:712-726. [PMID: 34076587 PMCID: PMC8171069 DOI: 10.1107/s2059798321001753] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Accepted: 02/12/2021] [Indexed: 11/10/2022] Open
Abstract
In this contribution, the current protocols for modelling covalent linkages within the CCP4 suite are considered. The mechanism used for modelling covalent linkages is reviewed: the use of dictionaries for describing changes to stereochemistry as a result of the covalent linkage and the application of link-annotation records to structural models to ensure the correct treatment of individual instances of covalent linkages. Previously, linkage descriptions were lacking in quality compared with those of contemporary component dictionaries. Consequently, AceDRG has been adapted for the generation of link dictionaries of the same quality as for individual components. The approach adopted by AceDRG for the generation of link dictionaries is outlined, which includes associated modifications to the linked components. A number of tools to facilitate the practical modelling of covalent linkages available within the CCP4 suite are described, including a new restraint-dictionary accumulator, the Make Covalent Link tool and AceDRG interface in Coot, the 3D graphical editor JLigand and the mechanisms for dealing with covalent linkages in the CCP4i2 and CCP4 Cloud environments. These integrated solutions streamline and ease the covalent-linkage modelling workflow, seamlessly transferring relevant information between programs. Current recommended practice is elucidated by means of instructive practical examples. By summarizing the different approaches to modelling linkages that are available within the CCP4 suite, limitations and potential pitfalls that may be encountered are highlighted in order to raise awareness, with the intention of improving the quality of future modelled covalent linkages in macromolecular complexes.
Collapse
Affiliation(s)
- Robert A. Nicholls
- Structural Studies, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, United Kingdom
| | - Robbie P. Joosten
- Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
- Oncode Institute, The Netherlands
| | - Fei Long
- Structural Studies, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, United Kingdom
| | - Marcin Wojdyr
- Global Phasing Limited, Sheraton House, Castle Park, Cambridge CB3 0AX, United Kingdom
| | - Andrey Lebedev
- CCP4, STFC Rutherford Appleton Laboratory, Chilton, Didcot OX11 0QX, United Kingdom
| | - Eugene Krissinel
- CCP4, STFC Rutherford Appleton Laboratory, Chilton, Didcot OX11 0QX, United Kingdom
| | - Lucrezia Catapano
- Structural Studies, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, United Kingdom
- Randall Centre for Cell and Molecular Biophysics, Faculty of Life Sciences and Medicine, King’s College London, London SE1 9RT, United Kingdom
| | - Marcus Fischer
- Chemical Biology and Therapeutics and Structural Biology, St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA
| | - Paul Emsley
- Structural Studies, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, United Kingdom
| | - Garib N. Murshudov
- Structural Studies, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, United Kingdom
| |
Collapse
|
10
|
Sietmann J, Ong M, Mück‐Lichtenfeld C, Daniliuc CG, Wahl JM. Desymmetrization of Prochiral Cyclobutanones via Nitrogen Insertion: A Concise Route to Chiral γ-Lactams. Angew Chem Int Ed Engl 2021; 60:9719-9723. [PMID: 33538070 PMCID: PMC8252468 DOI: 10.1002/anie.202100642] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Indexed: 01/08/2023]
Abstract
Asymmetric access to γ-lactams is achieved via a cyclobutanone ring expansion using widely available (1S,2R)-1-amino-2-indanol for chiral induction. Mechanistic analysis of the key N,O-ketal rearrangement reveals a Curtin-Hammett scenario, which enables a downstream stereoinduction (up to 88:12 dr) and is corroborated by spectroscopic, crystallographic, and computational studies. In combination with an easy deprotection protocol, this operationally simple sequence allows the synthesis of a range of optically pure γ-lactams, including those bearing all-carbon quaternary stereocenters. In addition, the formal synthesis of drug molecules baclofen, brivaracetam, and pregabalin further demonstrates the synthetic utility and highlights the general applicability of the presented method.
Collapse
Affiliation(s)
- Jan Sietmann
- Organisch-Chemisches InstitutWestfälische Wilhelms-UniversitätCorrensstrasse 3648149MünsterGermany
| | - Mike Ong
- Organisch-Chemisches InstitutWestfälische Wilhelms-UniversitätCorrensstrasse 3648149MünsterGermany
| | | | - Constantin G. Daniliuc
- Organisch-Chemisches InstitutWestfälische Wilhelms-UniversitätCorrensstrasse 3648149MünsterGermany
| | - Johannes M. Wahl
- Organisch-Chemisches InstitutWestfälische Wilhelms-UniversitätCorrensstrasse 3648149MünsterGermany
- Department ChemieJohannes Gutenberg-UniversitätDuesbergweg 10–1455128MainzGermany
| |
Collapse
|
11
|
Sietmann J, Ong M, Mück‐Lichtenfeld C, Daniliuc CG, Wahl JM. Desymmetrisierung von prochiralen Cyclobutanonen via Stickstoffinsertion: Ein einfacher Zugang zu chiralen γ‐Lactamen. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202100642] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Jan Sietmann
- Organisch-Chemisches Institut Westfälische Wilhelms-Universität Corrensstraße 36 48149 Münster Deutschland
| | - Mike Ong
- Organisch-Chemisches Institut Westfälische Wilhelms-Universität Corrensstraße 36 48149 Münster Deutschland
| | - Christian Mück‐Lichtenfeld
- Organisch-Chemisches Institut Westfälische Wilhelms-Universität Corrensstraße 36 48149 Münster Deutschland
| | - Constantin G. Daniliuc
- Organisch-Chemisches Institut Westfälische Wilhelms-Universität Corrensstraße 36 48149 Münster Deutschland
| | - Johannes M. Wahl
- Organisch-Chemisches Institut Westfälische Wilhelms-Universität Corrensstraße 36 48149 Münster Deutschland
- Department Chemie Johannes Gutenberg-Universität Duesbergweg 10–14 55128 Mainz Deutschland
| |
Collapse
|
12
|
Pashev A, Burdzhiev N, Stanoeva E. One-step route to tricyclic fused 1,2,3,4-tetrahydroisoquinoline systems via the Castagnoli-Cushman protocol. Beilstein J Org Chem 2020; 16:1456-1464. [PMID: 32647547 PMCID: PMC7323625 DOI: 10.3762/bjoc.16.121] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 06/09/2020] [Indexed: 11/29/2022] Open
Abstract
The Castagnoli-Cushman reaction of 3,4-dihydroisoquinolines with glutaric anhydride, its oxygen and sulfur analogues was investigated as a one-step approach to the benzo[a]quinolizidine system and its heterocyclic analogs. An extension towards the pyrrolo[2,1-a]isoquinoline system was achieved with the use of succinic anhydride. The results are evidence of an unexplored method for the access of the aforementioned tricyclic annelated systems incorporating a bridgehead nitrogen atom. The structures and relative configurations of the new compounds were established by means of 1D and 2D NMR techniques. The reactions between 1-methyldihydroisoquinoline and glutaric, diglycolic and succinic anhydrides yielded unexpected isoquinoline derivatives containing an exocyclic double bond. The compounds prepared bear the potential to become building blocks for future synthetic bioactive molecules.
Collapse
Affiliation(s)
- Aleksandar Pashev
- Sofia University “St. Kliment Ohridski”, Faculty of Chemistry and Pharmacy, 1, James Bourchier ave., 1164 Sofia, Bulgaria
- Medical University Pleven, Faculty of Pharmacy, 1, St. Kliment Ohridski str., 5800 Pleven, Bulgaria
| | - Nikola Burdzhiev
- Sofia University “St. Kliment Ohridski”, Faculty of Chemistry and Pharmacy, 1, James Bourchier ave., 1164 Sofia, Bulgaria
| | - Elena Stanoeva
- Sofia University “St. Kliment Ohridski”, Faculty of Chemistry and Pharmacy, 1, James Bourchier ave., 1164 Sofia, Bulgaria
| |
Collapse
|
13
|
Johnson BM, Shu YZ, Zhuo X, Meanwell NA. Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. J Med Chem 2020; 63:6315-6386. [PMID: 32182061 DOI: 10.1021/acs.jmedchem.9b01877] [Citation(s) in RCA: 310] [Impact Index Per Article: 77.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The applications of fluorine in drug design continue to expand, facilitated by an improved understanding of its effects on physicochemical properties and the development of synthetic methodologies that are providing access to new fluorinated motifs. In turn, studies of fluorinated molecules are providing deeper insights into the effects of fluorine on metabolic pathways, distribution, and disposition. Despite the high strength of the C-F bond, the departure of fluoride from metabolic intermediates can be facile. This reactivity has been leveraged in the design of mechanism-based enzyme inhibitors and has influenced the metabolic fate of fluorinated compounds. In this Perspective, we summarize the literature associated with the metabolism of fluorinated molecules, focusing on examples where the presence of fluorine influences the metabolic profile. These studies have revealed potentially problematic outcomes with some fluorinated motifs and are enhancing our understanding of how fluorine should be deployed.
Collapse
Affiliation(s)
- Benjamin M Johnson
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, 100 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Yue-Zhong Shu
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States
| | - Xiaoliang Zhuo
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, 100 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Nicholas A Meanwell
- Discovery Chemistry Platforms, Small Molecule Drug Discovery, Bristol Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States
| |
Collapse
|
14
|
Qian LL, Min XT, Hu YC, Shen BX, Yang SN, Wan B, Chen QA. Ruthenium(ii)-catalyzed intermolecular annulation of alkenyl sulfonamides with alkynes: access to bicyclic sultams. Chem Commun (Camb) 2020; 56:2614-2617. [PMID: 32016279 DOI: 10.1039/d0cc00093k] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
A ruthenium-catalyzed allylic C(sp3)-H activation strategy has been employed to develop an intermolecular coupling of alkenyl sulfonamides with alkynes. This protocol features the diastereoselective construction of [3.3.0] and [4.3.0] bicyclic sultams in one step.
Collapse
Affiliation(s)
- Lei-Lei Qian
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. and University of Chinese Academy of Sciences, 100049, Beijing, China
| | - Xiang-Ting Min
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. and University of Chinese Academy of Sciences, 100049, Beijing, China
| | - Yan-Cheng Hu
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
| | - Bing-Xue Shen
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. and University of Chinese Academy of Sciences, 100049, Beijing, China
| | - Sa-Na Yang
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. and University of Chinese Academy of Sciences, 100049, Beijing, China
| | - Boshun Wan
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
| | - Qing-An Chen
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
| |
Collapse
|
15
|
Pantaleão SQ, Philot EA, de Oliveira Almeida M, Lima AN, de Sairre MI, Scott AL, Honorio KM. Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4). Curr Top Med Chem 2019; 20:209-226. [PMID: 31878857 DOI: 10.2174/1568026620666191226101543] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 12/04/2019] [Accepted: 12/06/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND A strategy for the treatment of type II diabetes mellitus is the inhibition of the enzyme known as dipeptidyl peptidase-4 (DPP-4). AIMS This study aims to investigate the main interactions between DPP-4 and a set of inhibitors, as well as proposing potential candidates to inhibit this enzyme. METHODS We performed molecular docking studies followed by the construction and validation of CoMFA and CoMSIA models. The information provided from these models was used to aid in the search for new candidates to inhibit DPP-4 and the design of new bioactive ligands from structural modifications in the most active molecule of the studied series. RESULTS We were able to propose a set of analogues with biological activity predicted by the CoMFA and CoMSIA models, suggesting that our protocol can be used to guide the design of new DPP-4 inhibitors as drug candidates to treat diabetes. CONCLUSION Once the integration of the techniques mentioned in this article was effective, our strategy can be applied to design possible new DPP-4 inhibitors as candidates to treat diabetes.
Collapse
Affiliation(s)
- Simone Queiroz Pantaleão
- Center for Sciences Natural and Human, Federal University of ABC, Santo Andre, Sao Paulo, Brazil
| | - Eric Allison Philot
- Center for Mathematics, Computing and Cognition, Federal University of ABC, Santo Andre, Sao Paulo, Brazil
| | | | - Angelica Nakagawa Lima
- Center for Engineering, Modeling and Applied Social Sciences, Federal University of ABC, Santo André, Sao Paulo, Brazil
| | - Mirela Inês de Sairre
- Center for Sciences Natural and Human, Federal University of ABC, Santo Andre, Sao Paulo, Brazil
| | - Ana Ligia Scott
- Center for Mathematics, Computing and Cognition, Federal University of ABC, Santo Andre, Sao Paulo, Brazil
| | - Kathia Maria Honorio
- Center for Sciences Natural and Human, Federal University of ABC, Santo Andre, Sao Paulo, Brazil.,School of Arts, Sciences and Humanities, University of São Paulo, São Paulo, Brazil
| |
Collapse
|
16
|
Huang PK, Lin SR, Chang CH, Tsai MJ, Lee DN, Weng CF. Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV. Sci Rep 2019; 9:15585. [PMID: 31666589 PMCID: PMC6821704 DOI: 10.1038/s41598-019-52088-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 06/29/2018] [Indexed: 12/26/2022] Open
Abstract
Dipeptidyl peptidase IV (DPP IV) is a surface glycoprotein that can degrade glucagon like pepetide-1 (GLP-1) by decreasing blood sugar. Herbal medicines for diabetic therapy are widely used with acceptable efficacy but unsatisfied in advances. DPP IV was chosen as a template to employ molecular docking via Discovery Studio to search for natural phenolic compounds whether they have the inhibitory function of DPP IV. Then, docking candidates were validated and further performed signal pathway via Caco-2, C2C12, and AR42J cells. Lastly, a diet-induced diabetes in mice were applied to examine the efficacy and toxicity of hit natural phenolic products in long-term use (in vivo). After screening, curcumin, syringic acid, and resveratrol were found in high affinity with DPP IV enzymes. In enzymatic tests, curcumin and resveratrol showed potential inhibition of DPP IV. In vitro assays, curcumin inhibited of DPP IV activity in Caco-2 cells and ERK phosphorylation in C2C12 cells. Additionally, curcumin attenuated blood sugar in S961-treated C57BL/6 mice and in diet-induced diabetic ICR mice and long-term regulate HbA1c in diabetic mice. Curcumin targeted to DPP IV for reducing blood glucose, it possesses potential and alternative substitution of synthetic clinical drugs for the medication of diabetes.
Collapse
Affiliation(s)
- Po-Kai Huang
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, 97401, Taiwan
| | - Shian-Ren Lin
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, 97401, Taiwan
| | - Chia-Hsiang Chang
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, 97401, Taiwan
| | - May-Jwan Tsai
- Neural regeneration Laboratory, Neurological Institute, Taipei Veterans General Hospital, Taipei, 11217, Taiwan
| | - Der-Nan Lee
- Department of Biotechnology and Animal Science, National Ilan University, Ilan, 26047, Taiwan
| | - Ching-Feng Weng
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, 97401, Taiwan. .,Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
| |
Collapse
|
17
|
Xie Y, Shao L, Wang Q, Bai Y, Chen Z, Li N, Xu Y, Li Y, Yang G, Bian X. Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents. Bioorg Med Chem Lett 2018; 28:3731-3735. [PMID: 30343953 DOI: 10.1016/j.bmcl.2018.10.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 10/13/2018] [Accepted: 10/14/2018] [Indexed: 10/28/2022]
Abstract
Nitric oxide (NO) dysfunction has been found to be an important factor in both the development and progression of diabetic complications due to its many roles in the vascular system. Multifunctional compounds with hypoglycemic and endothelial protective action will be promising agents for the treatment of diabetes and its complications. In this study, a series of novel NO-donating sitagliptin derivatives and relevant metabolites were synthesized and evaluated as potential multifunctional hypoglycemic agents. All of synthetic compounds shown remarkable inhibitory activity against dipeptidyl peptidase IV (DPP-IV) in vitro and demonstrated excellent hypoglycemic activities in diabetic mice, similar to the activity of sitagliptin, and compounds T1-T4 shown different extents of NO-releasing abilities and potent antioxidant abilities in vivo. By screening in DPP-4, compound T4 was recognized as a potent DPP-4 inhibitor with the IC50 value of 0.060 μM. Docking study revealed compound T4 has a favorable binding mode. Furthermore, compounds T1-T4 exhibited different extents of NO-releasing abilities and excellent anti-platelet aggregation in vitro. The overall results suggested that T4 could help to the amelioration of endothelial dysfunction by reducing blood glucose, lessening oxidative stress and raising NO levels as well as inhibiting platelet aggregation. Based on this research, compound T4 deserves further investigation as potential new multifunctional anti-diabetic agent with antioxidant, anti-platelet aggregation and endothelial protective properties.
Collapse
Affiliation(s)
- Yundong Xie
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China; Department of Medicine, Tibet University of Nationalities, No. 6 Wenhui East Road, Xianyang, Shaanxi Province 712082, People's Republic of China.
| | - Lihua Shao
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China
| | - Qiutang Wang
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China
| | - Yue Bai
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China
| | - Zizhang Chen
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China
| | - Na Li
- Community Health Service Center of Daxing New District, No.233 Ziqiang West Road, Lianhu District, Xi'an, Shaanxi Province 710000, People's Republic of China
| | - Yanhong Xu
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China
| | - Yiping Li
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China
| | - Guangde Yang
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China.
| | - Xiaoli Bian
- College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province 710061, People's Republic of China.
| |
Collapse
|
18
|
Ojeda-Montes MJ, Gimeno A, Tomas-Hernández S, Cereto-Massagué A, Beltrán-Debón R, Valls C, Mulero M, Pujadas G, Garcia-Vallvé S. Activity and selectivity cliffs for DPP-IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening. Med Res Rev 2018; 38:1874-1915. [PMID: 29660786 DOI: 10.1002/med.21499] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 02/06/2018] [Accepted: 03/02/2018] [Indexed: 12/13/2022]
Abstract
The inhibition of dipeptidyl peptidase-IV (DPP-IV) has emerged over the last decade as one of the most effective treatments for type 2 diabetes mellitus, and consequently (a) 11 DPP-IV inhibitors have been on the market since 2006 (three in 2015), and (b) 74 noncovalent complexes involving human DPP-IV and drug-like inhibitors are available at the Protein Data Bank (PDB). The present review aims to (a) explain the most important activity cliffs for DPP-IV noncovalent inhibition according to the binding site structure of DPP-IV, (b) explain the most important selectivity cliffs for DPP-IV noncovalent inhibition in comparison with other related enzymes (i.e., DPP8 and DPP9), and (c) use the information deriving from this activity/selectivity cliff analysis to suggest how virtual screening protocols might be improved to favor the early identification of potent and selective DPP-IV inhibitors in molecular databases (because they have not succeeded in identifying selective DPP-IV inhibitors with IC50 ≤ 100 nM). All these goals are achieved with the help of available homology models for DPP8 and DPP9 and an analysis of the structure-activity studies used to develop the noncovalent inhibitors that form part of some of the complexes with human DPP-IV available at the PDB.
Collapse
Affiliation(s)
- María José Ojeda-Montes
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Aleix Gimeno
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Sarah Tomas-Hernández
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Adrià Cereto-Massagué
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Raúl Beltrán-Debón
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Cristina Valls
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Miquel Mulero
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain
| | - Gerard Pujadas
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain.,EURECAT, TECNIO, CEICS, Avinguda Universitat 1, Reus, Spain
| | - Santiago Garcia-Vallvé
- Research Group in Cheminformatics & Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Campus de Sescelades, Tarragona, Spain.,EURECAT, TECNIO, CEICS, Avinguda Universitat 1, Reus, Spain
| |
Collapse
|
19
|
Sarkale AM, Kumar A, Appayee C. Organocatalytic Approach for Short Asymmetric Synthesis of (R)-Paraconyl Alcohol: Application to the Total Syntheses of IM-2, SCB2, and A-Factor γ-Butyrolactone Autoregulators. J Org Chem 2018; 83:4167-4172. [DOI: 10.1021/acs.joc.8b00122] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Abhijeet M. Sarkale
- Discipline of Chemistry, Indian Institute of Technology Gandhinagar,
Palaj, Gandhinagar, Gujarat 382355, India
| | - Amit Kumar
- Discipline of Chemistry, Indian Institute of Technology Gandhinagar,
Palaj, Gandhinagar, Gujarat 382355, India
| | - Chandrakumar Appayee
- Discipline of Chemistry, Indian Institute of Technology Gandhinagar,
Palaj, Gandhinagar, Gujarat 382355, India
| |
Collapse
|
20
|
Rey-Rodriguez R, Jestin G, Gandon V, Grelier G, Retailleau P, Darses B, Dauban P, Gillaizeau I. Intermolecular Rhodium(II)-Catalyzed Allylic C(sp
3
)-H Amination of Cyclic Enamides. Adv Synth Catal 2018. [DOI: 10.1002/adsc.201701188] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Romain Rey-Rodriguez
- Institute of Organic and Analytical Chemistry, ICOA UMR 7311 CNRS; Université d'Orléans; rue de Chartres 45100 Orléans France
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud; Université Paris-Saclay; avenue de la terrasse 91198 Gif-sur-Yvette France
| | - Grégory Jestin
- Institute of Organic and Analytical Chemistry, ICOA UMR 7311 CNRS; Université d'Orléans; rue de Chartres 45100 Orléans France
| | - Vincent Gandon
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud; Université Paris-Saclay; avenue de la terrasse 91198 Gif-sur-Yvette France
- Institut de Chimie Moléculaire et des Matériaux d'Orsay, CNRS UMR 8182; Univ. Paris-Sud, Université Paris-Saclay; 91405 Orsay France
| | - Gwendal Grelier
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud; Université Paris-Saclay; avenue de la terrasse 91198 Gif-sur-Yvette France
| | - Pascal Retailleau
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud; Université Paris-Saclay; avenue de la terrasse 91198 Gif-sur-Yvette France
| | - Benjamin Darses
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud; Université Paris-Saclay; avenue de la terrasse 91198 Gif-sur-Yvette France
| | - Philippe Dauban
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud; Université Paris-Saclay; avenue de la terrasse 91198 Gif-sur-Yvette France
| | - Isabelle Gillaizeau
- Institute of Organic and Analytical Chemistry, ICOA UMR 7311 CNRS; Université d'Orléans; rue de Chartres 45100 Orléans France
| |
Collapse
|
21
|
Gérardy R, Winter M, Horn CR, Vizza A, Van Hecke K, Monbaliu JCM. Continuous-Flow Preparation of γ-Butyrolactone Scaffolds from Renewable Fumaric and Itaconic Acids under Photosensitized Conditions. Org Process Res Dev 2017. [DOI: 10.1021/acs.oprd.7b00314] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Romaric Gérardy
- Center
for Integrated Technology and Organic Synthesis, Department of Chemistry, University of Liège, B-4000 Liège (Sart Tilman), Belgium
| | - Marc Winter
- Corning
Reactor Technologies, Corning SAS, 7 bis Avenue de Valvins, CS 70156
Samois sur Seine, 77215 Avon Cedex, France
| | - Clemens R. Horn
- Corning
Reactor Technologies, Corning SAS, 7 bis Avenue de Valvins, CS 70156
Samois sur Seine, 77215 Avon Cedex, France
| | - Alessandra Vizza
- Corning
Reactor Technologies, Corning SAS, 7 bis Avenue de Valvins, CS 70156
Samois sur Seine, 77215 Avon Cedex, France
| | - Kristof Van Hecke
- XStruct,
Department of Chemistry, Ghent University, Krijgslaan 281-S3, B-9000 Ghent, Belgium
| | - Jean-Christophe M. Monbaliu
- Center
for Integrated Technology and Organic Synthesis, Department of Chemistry, University of Liège, B-4000 Liège (Sart Tilman), Belgium
| |
Collapse
|
22
|
Deng X, Han L, Zhou J, Zhang H, Li Q. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. Bioorg Chem 2017; 75:357-367. [PMID: 29096096 DOI: 10.1016/j.bioorg.2017.10.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 10/12/2017] [Accepted: 10/22/2017] [Indexed: 01/02/2023]
Abstract
Dipeptidyl peptidase-IV (DPP-4) is a validated target for T2DM treatment. We previously reported a novel series of triazole-based uracil derivatives bearing aliphatic carboxylic acids with potent DPP-4 inhibitory activities in vitro, but these compounds showed poor hypoglycemic effects in vivo. Herein we further optimized the triazole moiety by amidation of the carboxylic acid to improve in vivo activities. Two series of compounds 3a-f and 4a-g were designed and synthesized. By screening in DPP-4, compound 4c was identified as a potent DPP-4 inhibitor with the IC50 value of 28.62 nM. Docking study revealed compound 4c has a favorable binding mode and interpreted the SAR of these analogs. DPP-8 and DPP-9 tests indicated compound 4c had excellent selectivity over DPP-8 and DPP-9. Further in vivo evaluations revealed that compound 4c showed more potent hypoglycemic activity than its corresponding carboxylic acid in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice. The overall results have shown that compound 4c could be a promising lead for further development of novel DPP-4 agents treating T2DM.
Collapse
Affiliation(s)
- Xiaoyan Deng
- Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, PR China
| | - Li Han
- Center of Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, PR China
| | - Jinpei Zhou
- Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, PR China
| | - Huibin Zhang
- Center of Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, PR China
| | - Qing Li
- Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, PR China; Center of Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, PR China.
| |
Collapse
|
23
|
Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors. Bioorg Chem 2017; 72:345-358. [PMID: 28302310 DOI: 10.1016/j.bioorg.2017.03.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 03/02/2017] [Accepted: 03/03/2017] [Indexed: 12/15/2022]
Abstract
Type 2 diabetes mellitus (T2DM) is one of the major global metabolic disorders characterized by insulin resistance and chronic hyperglycemia. Inhibition of the enzyme, dipeptidyl peptidase-4 (DPP-4) has been proved as successful and safe therapy for the treatment of T2DM since last decade. In order to design novel DPP-4 inhibitors, various in silico studies such as 3D-QSAR, pharmacophore modeling and virtual screening were performed and on the basis of the combined results of them, total 50 triazolo[5,1-c][1,2,4]triazine derivatives were designed and mapped on the best pharmacophore model. From this, best 25 derivatives were docked onto the active site of DPP-4 enzyme and in silico ADMET properties were also predicted. Finally, top 17 derivatives were synthesized and characterized using FT-IR, Mass, 1H NMR and 13C NMR spectroscopy. Purity of compounds was checked using HPLC. These derivatives were then evaluated for in vitro DPP-4 inhibition. The most promising compound 15q showed 28.05μM DPP-4 IC50 with 8-10-fold selectivity over DPP-8 and DPP-9 so selected for further in vivo anti-diabetic evaluation. During OGTT in normal C57BL/6J mice, compound 15q reduced blood glucose excursion in a dose-dependent manner. Chronic treatment for 28days with compound 15q improved the serum glucose levels in type 2 diabetic Sprague Dawley rats wherein diabetes was induced by high fat diet and low dose streptozotocin. This suggested that compound 15q is a moderately potent and selective hit molecule which can be further optimized structurally to increase the efficacy and overall pharmacological profile as DPP-4 inhibitor.
Collapse
|
24
|
Pashev AS, Burdzhiev NT, Stanoeva ER. Synthetic Approaches toward the Benzo[a]quinolizidine System. A Review. ORG PREP PROCED INT 2016. [DOI: 10.1080/00304948.2016.1234820] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
25
|
Nojima H, Kanou K, Terashi G, Takeda-Shitaka M, Inoue G, Atsuda K, Itoh C, Iguchi C, Matsubara H. Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor. BMC STRUCTURAL BIOLOGY 2016; 16:11. [PMID: 27491540 PMCID: PMC4974693 DOI: 10.1186/s12900-016-0062-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 07/29/2016] [Indexed: 12/21/2022]
Abstract
Background We comprehensively analyzed X-ray cocrystal structures of dipeptidyl peptidase IV (DPP-4) and its inhibitor to clarify whether DPP-4 alters its general or partial structure according to the inhibitor used and whether DPP-4 has a common rule for inhibitor binding. Results All the main and side chains in the inhibitor binding area were minimally altered, except for a few side chains, despite binding to inhibitors of various shapes. Some residues (Arg125, Glu205, Glu206, Tyr662 and Asn710) in the area had binding modes to fix a specific atom of inhibitor to a particular spatial position in DPP-4. We found two specific water molecules that were common to 92 DPP-4 structures. The two water molecules were close to many inhibitors, and seemed to play two roles: maintaining the orientation of the Glu205 and Glu206 side chains through a network via the water molecules, and arranging the inhibitor appropriately at the S2 subsite. Conclusions Our study based on high-quality resources may provide a necessary minimum consensus to help in the discovery of a novel DPP-4 inhibitor that is commercially useful. Electronic supplementary material The online version of this article (doi:10.1186/s12900-016-0062-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Hiroyuki Nojima
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
| | - Kazuhiko Kanou
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.,Present address: Infectious Disease Surveillance Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan
| | - Genki Terashi
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Mayuko Takeda-Shitaka
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Gaku Inoue
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Koichiro Atsuda
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Chihiro Itoh
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Chie Iguchi
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Hajime Matsubara
- School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| |
Collapse
|
26
|
Wang Y, Wang Q, Zhu J. Chiral Phosphoric Acid-Catalyzed Enantioselective Formal [3+2] Cycloaddition of Azomethine Imines with Enecarbamates. Chemistry 2016; 22:8084-8. [DOI: 10.1002/chem.201601548] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Indexed: 12/19/2022]
Affiliation(s)
- Yang Wang
- Laboratory of Synthesis and Natural Products; Institute of Chemical Sciences and Engineering; Ecole Polytechnique Fédérale de Lausanne, EPFL-SB-ISIC-LSPN, BCH 5304; 1015 Lausanne Switzerland
| | - Qian Wang
- Laboratory of Synthesis and Natural Products; Institute of Chemical Sciences and Engineering; Ecole Polytechnique Fédérale de Lausanne, EPFL-SB-ISIC-LSPN, BCH 5304; 1015 Lausanne Switzerland
| | - Jieping Zhu
- Laboratory of Synthesis and Natural Products; Institute of Chemical Sciences and Engineering; Ecole Polytechnique Fédérale de Lausanne, EPFL-SB-ISIC-LSPN, BCH 5304; 1015 Lausanne Switzerland
| |
Collapse
|
27
|
Kuhn B, Guba W, Hert J, Banner D, Bissantz C, Ceccarelli S, Haap W, Körner M, Kuglstatter A, Lerner C, Mattei P, Neidhart W, Pinard E, Rudolph MG, Schulz-Gasch T, Woltering T, Stahl M. A Real-World Perspective on Molecular Design. J Med Chem 2016; 59:4087-102. [PMID: 26878596 DOI: 10.1021/acs.jmedchem.5b01875] [Citation(s) in RCA: 84] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
We present a series of small molecule drug discovery case studies where computational methods were prospectively employed to impact Roche research projects, with the aim of highlighting those methods that provide real added value. Our brief accounts encompass a broad range of methods and techniques applied to a variety of enzymes and receptors. Most of these are based on judicious application of knowledge about molecular conformations and interactions: filling of lipophilic pockets to gain affinity or selectivity, addition of polar substituents, scaffold hopping, transfer of SAR, conformation analysis, and molecular overlays. A case study of sequence-driven focused screening is presented to illustrate how appropriate preprocessing of information enables effective exploitation of prior knowledge. We conclude that qualitative statements enabling chemists to focus on promising regions of chemical space are often more impactful than quantitative prediction.
Collapse
Affiliation(s)
- Bernd Kuhn
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Wolfgang Guba
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Jérôme Hert
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - David Banner
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Caterina Bissantz
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Simona Ceccarelli
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Wolfgang Haap
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Matthias Körner
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Andreas Kuglstatter
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Christian Lerner
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Patrizio Mattei
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Werner Neidhart
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Emmanuel Pinard
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Markus G Rudolph
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Tanja Schulz-Gasch
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Thomas Woltering
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Martin Stahl
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070 Basel, Switzerland
| |
Collapse
|
28
|
Kramer C, Fuchs JE, Liedl KR. Strong nonadditivity as a key structure-activity relationship feature: distinguishing structural changes from assay artifacts. J Chem Inf Model 2015; 55:483-94. [PMID: 25760829 PMCID: PMC4372821 DOI: 10.1021/acs.jcim.5b00018] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Nonadditivity
in protein–ligand affinity data represents
highly instructive structure–activity relationship (SAR) features
that indicate structural changes and have the potential to guide rational
drug design. At the same time, nonadditivity is a challenge for both
basic SAR analysis as well as many ligand-based data analysis techniques
such as Free-Wilson Analysis and Matched Molecular Pair analysis,
since linear substituent contribution models inherently assume additivity
and thus do not work in such cases. While structural causes for nonadditivity
have been analyzed anecdotally, no systematic approaches to interpret
and use nonadditivity prospectively have been developed yet. In this
contribution, we lay the statistical framework for systematic analysis
of nonadditivity in a SAR series. First, we develop a general metric
to quantify nonadditivity. Then, we demonstrate the non-negligible
impact of experimental uncertainty that creates apparent nonadditivity,
and we introduce techniques to handle experimental uncertainty. Finally,
we analyze public SAR data sets for strong nonadditivity and use recourse
to the original publications and available X-ray structures to find
structural explanations for the nonadditivity observed. We find that
all cases of strong nonadditivity (ΔΔpKi and ΔΔpIC50 > 2.0 log units)
with sufficient structural information to generate reasonable hypothesis
involve changes in binding mode. With the appropriate statistical
basis, nonadditivity analysis offers a variety of new attempts for
various areas in computer-aided drug design, including the validation
of scoring functions and free energy perturbation approaches, binding
pocket classification, and novel features in SAR analysis tools.
Collapse
Affiliation(s)
- Christian Kramer
- †Department of Theoretical Chemistry, Faculty for Chemistry and Pharmacy, Center for Molecular Biosciences Innsbruck (CMBI), Leopold-Franzens University Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria
| | - Julian E Fuchs
- †Department of Theoretical Chemistry, Faculty for Chemistry and Pharmacy, Center for Molecular Biosciences Innsbruck (CMBI), Leopold-Franzens University Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria.,‡Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Klaus R Liedl
- †Department of Theoretical Chemistry, Faculty for Chemistry and Pharmacy, Center for Molecular Biosciences Innsbruck (CMBI), Leopold-Franzens University Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria
| |
Collapse
|
29
|
Ji X, Xia C, Wang J, Su M, Zhang L, Dong T, Li Z, Wan X, Li J, Li J, Zhao L, Gao Z, Jiang H, Liu H. Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2014; 86:242-56. [PMID: 25164763 DOI: 10.1016/j.ejmech.2014.08.059] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2014] [Revised: 08/15/2014] [Accepted: 08/16/2014] [Indexed: 01/25/2023]
Abstract
Based on the previous work in our group and the principle of computer-aided drug design, a series of novel β-amino pyrrole-2-carbonitrile derivatives was designed and synthesized. Compounds 8l and 9l were efficacious and selective DPP4 inhibitors resulting in decreased blood glucose in vivo. Compound 8l had moderate DPP4 inhibitory activity (IC50 = 0.05 μM) and good oral bioavailability (F = 53.2%). Compound 9l showed excellent DPP4 inhibitory activity (IC50 = 0.01 μM), good selectivity (selective ratio: DPP8/DPP4 = 898.00; DPP9/DPP4 = 566.00) against related peptidases, and good efficacy in an oral glucose tolerance tests in ICR mice and moderate PK profiles (F = 22.8%, t1/2 = 2.74 h). Moreover, compound 9l did not block hERG channel and exhibited no inhibition of liver metabolic enzymes such as CYP2C9.
Collapse
Affiliation(s)
- Xun Ji
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China; School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, People's Republic of China
| | - Chunmei Xia
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Jiang Wang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Mingbo Su
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China; East China of Normal University, 3663 Zhongshan Road, Shanghai 200062, People's Republic of China
| | - Lei Zhang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Tiancheng Dong
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Zeng Li
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Xia Wan
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Jingya Li
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Jia Li
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China.
| | - Linxiang Zhao
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, People's Republic of China
| | - Zhaobing Gao
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China
| | - Hualiang Jiang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China; School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, People's Republic of China.
| | - Hong Liu
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People's Republic of China.
| |
Collapse
|
30
|
Patel BD, Ghate MD. 3D-QSAR studies of dipeptidyl peptidase-4 inhibitors using various alignment methods. Med Chem Res 2014. [DOI: 10.1007/s00044-014-1178-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Kuhlmann O, Carlile D, Noe J, Bentley D. Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. J Drug Assess 2014; 3:28-37. [PMID: 27536451 PMCID: PMC4937633 DOI: 10.3109/21556660.2014.900065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/27/2014] [Indexed: 11/25/2022] Open
Abstract
Objective The primary objective of this study was to investigate the interaction potential of carmegliptin with P-glycoprotein transporter in vitro and in vivo. A secondary objective was to investigate the safety and tolerability of carmegliptin alone or co-administered with verapamil. Research design and methods The inhibition potential of carmegliptin was tested in vitro and in a non-randomized open-label study in 16 healthy male volunteers. On day 1 a single dose of carmegliptin (150 mg) was given, followed by a single dose of verapamil (80 mg) on day 7, on day 10 a single dose of carmegliptin (150 mg) together with verapamil (80 mg t.i.d.), and verapamil (80 mg t.i.d.) on days 11–14. Finally, on day 15 a single dose of 150 mg carmegliptin together with 80 mg t.i.d. verapamil was administered. Pharmacokinetic and safety parameters were assessed. Results Carmegliptin showed in vitro a low cell permeability and was a good substrate for human MDR1 cells. When carmegliptin was taken with verapamil, the mean exposure and Cmax to carmegliptin increased by 29% and 53%, respectively. Increases in exposure were slightly greater on the sixth day of verapamil dosing than on the first day. Verapamil Cmax was 17% lower on average when given with carmegliptin than when verapamil was taken alone, and similar trends were apparent in corresponding norverapamil pharmacokinetics. All reported adverse events (n = 28) were mild in intensity, and verapamil had no apparent effect on the pattern or incidence of events. Conclusions In vitro, carmegliptin is a substrate but not an inhibitor of human Pgp. Consistently, the co-administration of carmegliptin with verapamil altered the pharmacokinetics of carmegliptin slightly and moderately increased the exposure. Peak exposure of verapamil and its metabolite norverapamil tended to be lower when co-administered with carmegliptin. The combination of carmegliptin and verapamil was generally well tolerated. Although the observed overall changes in pharmacokinetics were small and dose adjustments in clinics are currently not expected, co-administration of carmegliptin with Pgp inhibitors should be carefully monitored in future clinical trials.
Collapse
Affiliation(s)
- Olaf Kuhlmann
- Pharmaceutical Sciences, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., BaselSwitzerland
| | | | - Johannes Noe
- Oncology Biomarker Development (OBD), F. Hoffmann-La Roche Ltd., BaselSwitzerland
| | | |
Collapse
|
32
|
Ji X, Su M, Wang J, Deng G, Deng S, Li Z, Tang C, Li J, Li J, Zhao L, Jiang H, Liu H. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2014; 75:111-22. [PMID: 24531224 DOI: 10.1016/j.ejmech.2014.01.021] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2013] [Revised: 01/08/2014] [Accepted: 01/15/2014] [Indexed: 01/30/2023]
Abstract
A series of novel hetero-aromatic moieties substituted α-amino pyrrole-2-carbonitrile derivatives was designed and synthesized based on structure-activity relationships (SARs) of pyrrole-2-carbonitrile inhibitors. All compounds demonstrated good dipeptidyl peptidase IV (DPP4) inhibitory activities (IC50 = 0.004-113.6 μM). Moreover, compounds 6h (IC50 = 0.004 μM) and 6n (IC50 = 0.01 μM) showed excellent inhibitory activities against DPP4, good selectivity (compound 6h, selective ratio: DPP8/DPP4 = 450.0; DPP9/DPP4 = 375.0; compound 6n, selective ratio: DPP8/DPP4 = 470.0; DPP9/DPP4 = 750.0) and good efficacy in an oral glucose tolerance test in ICR mice. Furthermore, compounds 6h and 6n demonstrated moderate PK properties (compound 6h, F% = 37.8%, t1/2 = 1.45 h; compound 6n, F% = 16.8%, t1/2 = 3.64 h).
Collapse
Affiliation(s)
- Xun Ji
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wen Hua Road, Shenyang, Liaoning 110016, PR China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Mingbo Su
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China; East China of Normal University, 3663 Zhongshan Road, Shanghai 200062, PR China
| | - Jiang Wang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Guanghui Deng
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Sisi Deng
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Zeng Li
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Chunlan Tang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Jingya Li
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Jia Li
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China.
| | - Linxiang Zhao
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wen Hua Road, Shenyang, Liaoning 110016, PR China
| | - Hualiang Jiang
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wen Hua Road, Shenyang, Liaoning 110016, PR China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China
| | - Hong Liu
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, PR China.
| |
Collapse
|
33
|
Patel BD, Ghate MD. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem 2014; 74:574-605. [PMID: 24531198 DOI: 10.1016/j.ejmech.2013.12.038] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 11/28/2013] [Accepted: 12/27/2013] [Indexed: 02/08/2023]
Abstract
Dipeptidyl peptidase-4 (DPP-4) is one of the widely explored novel targets for Type 2 diabetes mellitus (T2DM) currently. Research has been focused on the strategy to preserve the endogenous glucagon like peptide (GLP)-1 activity by inhibiting the DPP-4 action. The DPP-4 inhibitors are weight neutral, well tolerated and give better glycaemic control over a longer duration of time compared to existing conventional therapies. The journey of DPP-4 inhibitors in the market started from the launch of sitagliptin in 2006 to latest drug teneligliptin in 2012. This review is mainly focusing on the recent medicinal aspects and advancements in the designing of DPP-4 inhibitors with the therapeutic potential of DPP-4 as a target to convey more clarity in the diffused data.
Collapse
Affiliation(s)
- Bhumika D Patel
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad 382481, Gujarat, India.
| | - Manjunath D Ghate
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad 382481, Gujarat, India
| |
Collapse
|
34
|
Baumann M, Baxendale IR. An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles. Beilstein J Org Chem 2013. [DOI: 10.3762/bjoc.9.265 pmid: 24204439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
This review which is the second in this series summarises the most common synthetic routes as applied to the preparation of many modern pharmaceutical compounds categorised as containing a six-membered heterocyclic ring. The reported examples are based on the top retailing drug molecules combining synthetic information from both scientific journals and the wider patent literature. It is hoped that this compilation, in combination with the previously published review on five-membered rings, will form a comprehensive foundation and reference source for individuals interested in medicinal, synthetic and preparative chemistry.
Collapse
|
35
|
Baumann M, Baxendale IR. An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles. Beilstein J Org Chem 2013; 9:2265-319. [PMID: 24204439 PMCID: PMC3817479 DOI: 10.3762/bjoc.9.265] [Citation(s) in RCA: 527] [Impact Index Per Article: 47.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Accepted: 10/09/2013] [Indexed: 12/13/2022] Open
Abstract
This review which is the second in this series summarises the most common synthetic routes as applied to the preparation of many modern pharmaceutical compounds categorised as containing a six-membered heterocyclic ring. The reported examples are based on the top retailing drug molecules combining synthetic information from both scientific journals and the wider patent literature. It is hoped that this compilation, in combination with the previously published review on five-membered rings, will form a comprehensive foundation and reference source for individuals interested in medicinal, synthetic and preparative chemistry.
Collapse
Affiliation(s)
- Marcus Baumann
- Department of Chemistry, University of Durham, South Road, Durham, DH1 3LE, UK
| | | |
Collapse
|
36
|
Rassadin VA, Grosheva DS, Tomashevskii AA, Sokolov VV. Methods of Sultam Synthesis. Chem Heterocycl Compd (N Y) 2013. [DOI: 10.1007/s10593-013-1231-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Thirup S, Gupta V, Quistgaard EM. Up, down, and around: identifying recurrent interactions within and between super-secondary structures in β-propellers. Methods Mol Biol 2013; 932:35-50. [PMID: 22987345 DOI: 10.1007/978-1-62703-065-6_3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The examination and analysis of super-secondary structures or other specific structural patterns associated with particular functions, sequence motifs, or structural contexts require that the set of structures examined shares the same feature. This seems obvious but in practice this may often present problems such as identifying complete sets of data avoiding false positives. In the case of the β-propeller structures the symmetry of the propeller creates problems for many structure similarity search programs. Here we present a procedure that will identify propeller structures in PDB and assign them to the different N-propeller types. In addition we outline methods to examine similarities and differences within and between the four stranded up-and-down blades of the β-propeller.
Collapse
Affiliation(s)
- Søren Thirup
- Department of Molecular Biology, MIND Centre, CARB Centre, Aarhus University, Aarhus, Denmark.
| | | | | |
Collapse
|
38
|
Erasmus E, Swarts JC. Intramolecular communication and electrochemical observation of the 17-electron ruthenocenium cation in fluorinated ruthenocene-containing β-diketones; polymorphism of C10H21 and C10F21 derivatives. NEW J CHEM 2013. [DOI: 10.1039/c3nj00354j] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
39
|
Wei C, Desheng L, Jian G, Fang L, Lingling G, Mingjuan J. Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV. J Mol Model 2012; 19:1167-77. [PMID: 23151852 DOI: 10.1007/s00894-012-1653-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2012] [Accepted: 10/15/2012] [Indexed: 02/01/2023]
Abstract
The aminobenzo[a]quinolizines were investigated as a novel class of DPP-IV inhibitors. The stereochemistry of this class plays an important role in the bioactivity. In this study, the mechanisms of how different configuration of three chiral centers of this class influences the binding affinity were investigated by molecular dynamics simulations, free energy decomposition analysis. The S configuration for chiral center 3* is decisive for isomers to maintain high bioactivity; the chirality effect of chiral center 2* on the binding affinity is largely dependent, while the S configuration for chiral center 2* is preferable to R configuration for the bioactivity gain; the effect of chiral center 11b* on the binding affinity is insignificant. The chirality specificity for three chiral centers is responsible for distinction of two van der Waals contacts with Tyr547 and Phe357, and of H-bonding interactions with Arg125 and Glu206. Particularly, the Arg125 to act as a bridge in the H-bonding network contributes to stable H-bonding interactions of isomer in DPP-IV active site.
Collapse
Affiliation(s)
- Cui Wei
- College of Chemistry and Chemical Engineering, Graduate University of the Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | | | | | | | | | | |
Collapse
|
40
|
Fischer H, Atzpodien EA, Csato M, Doessegger L, Lenz B, Schmitt G, Singer T. In Silico Assay for Assessing Phospholipidosis Potential of Small Druglike Molecules: Training, Validation, and Refinement Using Several Data Sets. J Med Chem 2012; 55:126-39. [DOI: 10.1021/jm201082a] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Holger Fischer
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Elke-Astrid Atzpodien
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Miklos Csato
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Lucette Doessegger
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Barbara Lenz
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Georg Schmitt
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Thomas Singer
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| |
Collapse
|
41
|
Lee KM, Kim JC, Kang P, Lee WK, Eum H, Ha HJ. Chiral aziridine-2-carboxylates: versatile precursors for functionalized tetrahydroisoquinoline (THIQ) containing heterocycles. Tetrahedron 2012. [DOI: 10.1016/j.tet.2011.11.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
42
|
Abrecht S, Adam JM, Bromberger U, Diodone R, Fettes A, Fischer R, Goeckel V, Hildbrand S, Moine G, Weber M. An Efficient Process for the Manufacture of Carmegliptin. Org Process Res Dev 2011. [DOI: 10.1021/op2000207] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Stefan Abrecht
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Jean-Michel Adam
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Ulrike Bromberger
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Ralph Diodone
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Alec Fettes
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Rolf Fischer
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Volker Goeckel
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Stefan Hildbrand
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Gérard Moine
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Martin Weber
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| |
Collapse
|
43
|
Adam JM, Foricher J, Hanlon S, Lohri B, Moine G, Schmid R, Stahr H, Weber M, Wirz B, Zutter U. Development of a Scalable Synthesis of (S)-3-Fluoromethyl-γ-butyrolactone, Building Block for Carmegliptin’s Lactam Moiety. Org Process Res Dev 2011. [DOI: 10.1021/op200019k] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jean-Michel Adam
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Joseph Foricher
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Steven Hanlon
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Bruno Lohri
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Gérard Moine
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Rudolf Schmid
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Helmut Stahr
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Martin Weber
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Beat Wirz
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Ulrich Zutter
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, †pRED, Pharma Research and Early Development, Process Research and Synthesis, and ‡Pharma Technical Development Actives, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| |
Collapse
|
44
|
Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2011; 21:1366-70. [DOI: 10.1016/j.bmcl.2011.01.041] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Revised: 01/07/2011] [Accepted: 01/11/2011] [Indexed: 10/18/2022]
|
45
|
Andrews KM, Beebe DA, Benbow JW, Boyer DA, Doran SD, Hui Y, Liu S, McPherson RK, Neagu C, Parker JC, Piotrowski DW, Schneider SR, Treadway JL, VanVolkenberg MA, Zembrowski WJ. 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2011; 21:1810-4. [DOI: 10.1016/j.bmcl.2011.01.055] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Revised: 01/13/2011] [Accepted: 01/14/2011] [Indexed: 10/18/2022]
|
46
|
Kuhlmann O, Paehler A, Weick I, Funk C, Pantze M, Zell M, Timm U. Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys. Xenobiotica 2010; 40:840-52. [DOI: 10.3109/00498254.2010.519406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|